Line 20: |
Line 20: |
| |- | | |- |
| |CHAPTER 2 (EPITHELIAL TUMOURS OF THE BREAST) | | |CHAPTER 2 (EPITHELIAL TUMOURS OF THE BREAST) |
− | |Disease
| |
| | | | | |
| + | ---- |
| + | | |
| + | ---- |
| | | | | |
| + | ---- |
| | | | | |
| + | ---- |
| | | | | |
| + | ---- |
| | | | | |
| + | ---- |
| | | | | |
| + | ---- |
| | | | | |
| + | ---- |
| | | | | |
| + | ---- |
| |- | | |- |
| |Usual Ductal Hyperplasia | | |Usual Ductal Hyperplasia |
Line 311: |
Line 320: |
| | | | | |
| |- | | |- |
− | |Acinic Cell Carcinoma||Disease|| | + | |[[BRST5:Acinic Cell Carcinoma|Acinic Cell Carcinoma]]||Disease||Patricija Zot |
− | | | + | |2/28/2024 |
− | |
| |
− | |
| |
| | | | | |
| + | |PENDING |
| | | | | |
| + | |Katherine Geiersbach |
| | | | | |
| | | | | |
| |- | | |- |
− | |[[Adenoid Cystic Carcinoma]]||Disease||Katherine Geiersbach / Jun Liao | + | |[[BRST5:Adenoid Cystic Carcinoma|Adenoid Cystic Carcinoma]]||Disease||Katherine Geiersbach / Jun Liao |
| |10/12/02022 | | |10/12/02022 |
| |11/11/2023 | | |11/11/2023 |
Line 329: |
Line 338: |
| |2021 template added | | |2021 template added |
| |- | | |- |
− | |[[Secretory Carcinoma]]||Disease||Hui Chen / Morteza Seifi | + | |[[BRST5:Secretory Carcinoma|Secretory Carcinoma]]||Disease||Hui Chen / Morteza Seifi |
| |10/12/2022 | | |10/12/2022 |
| |11/11/2023 | | |11/11/2023 |
− | |PENDING | + | |COMPLETE |
| | | | | |
| |Katherine Geiersbach | | |Katherine Geiersbach |
Line 356: |
Line 365: |
| | | | | |
| |- | | |- |
− | |[[Tall Cell Carcinoma with Reversed Polarity]]||Disease||H. Evin Gulbahce | + | |[[BRST5:Tall Cell Carcinoma with Reversed Polarity|Tall Cell Carcinoma with Reversed Polarity]]||Disease||H. Evin Gulbahce |
| |8/11/2023 | | |8/11/2023 |
| |10/11/2023 | | |10/11/2023 |
Line 382: |
Line 391: |
| | | | | |
| | | | | |
| + | |- |
| + | |CHAPTER 3 (FIBROEPITHELIAL TUMOURS AND HAMARTOMAS OF THE BREAST) |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| |- | | |- |
| |Hamartoma||Disease|| | | |Hamartoma||Disease|| |
Line 392: |
Line 421: |
| | | | | |
| |- | | |- |
− | |[[Fibroadenoma]]||Disease||H. Evin Gulbahce / Patricija Zot | + | |[[BRST5:Fibroadenoma|Fibroadenoma]]||Disease||H. Evin Gulbahce / Patricija Zot |
| |8/11/2023 | | |8/11/2023 |
| |11/11/2023 | | |11/11/2023 |
Line 401: |
Line 430: |
| |2021 template added | | |2021 template added |
| |- | | |- |
− | |[[Phyllodes Tumour]]||Disease||Emilie Lalonde / H. Evin Gulbahce /Katherine Geiersbach | + | |[[BRST5:Phyllodes Tumour|Phyllodes Tumour]]||Disease||Emilie Lalonde / H. Evin Gulbahce /Katherine Geiersbach |
| |8/11/2023 | | |8/11/2023 |
| |11/11/2023 | | |11/11/2023 |
Line 409: |
Line 438: |
| | | | | |
| |2021 template added | | |2021 template added |
| + | |- |
| + | |CHAPTER 4 (TUMOURS OF THE NIPPLE) |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| |- | | |- |
| |Syringomatous Tumour||Disease|| | | |Syringomatous Tumour||Disease|| |
Line 436: |
Line 485: |
| | | | | |
| | | | | |
| + | |- |
| + | |CHAPTER 5 (MESENCHYMAL TUMOURS OF THE BREAST) |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| |- | | |- |
| |Haemangioma||Disease|| | | |Haemangioma||Disease|| |
Line 509: |
Line 578: |
| | | | | |
| |- | | |- |
− | |[[Inflammatory Myofibroblastic Tumour]]||Disease||Yajuan Liu | + | |[[BRST5:Inflammatory Myofibroblastic Tumour|Inflammatory Myofibroblastic Tumour]]||Disease||Yajuan Liu |
| |8/11/2023 | | |8/11/2023 |
| |11/11/2023 | | |11/11/2023 |
Line 598: |
Line 667: |
| | | | | |
| | | | | |
| + | |- |
| + | |CHAPTER 6 (HAEMATOLYMPHOID TUMOURS OF THE BREAST) |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| |- | | |- |
| |Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)||Disease|| | | |Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)||Disease|| |
Line 643: |
Line 732: |
| | | | | |
| | | | | |
| + | |- |
| + | |CHAPTER 7 (TUMOURS OF THE MALE BREAST) |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| |- | | |- |
| |Gynaecomastia||Disease|| | | |Gynaecomastia||Disease|| |
Line 679: |
Line 788: |
| | | | | |
| | | | | |
| + | |- |
| + | |CHAPTER 8 (GENETIC TUMOUR SYNDROMES OF THE BREAST) |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| + | | |
| + | ---- |
| |- | | |- |
| |BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome||Disease||Constance Albarracin / Katherine Geiersbach | | |BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome||Disease||Constance Albarracin / Katherine Geiersbach |
Line 761: |
Line 890: |
| |NOT YET CREATED - See page "[[Neurofibromatosis Type 1 (NF1)]]" in GTS5 book. Will later add breast book link redirecting to this GTS5 book page (need to correlate with related volunteer page - [[GTS5:Volunteer Assignments and Opportunities]]). | | |NOT YET CREATED - See page "[[Neurofibromatosis Type 1 (NF1)]]" in GTS5 book. Will later add breast book link redirecting to this GTS5 book page (need to correlate with related volunteer page - [[GTS5:Volunteer Assignments and Opportunities]]). |
| |- | | |- |
− | |[[Polygenic Component of Breast Cancer Susceptibility]] | + | |[[BRST5:Polygenic Component of Breast Cancer Susceptibility|Polygenic Component of Breast Cancer Susceptibility]] |
| |Disease | | |Disease |
| | | | | |